Late-breaking Dupixent® (dupilumab)
data at ERS 2022 show consistent efficacy and safety
profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
- Results from the longest global Phase 3 open-label extension trial in this age group in asthma show sustained improvement in lung function, low rate of asthma attacks and a consistent safety profile for up to two years
- Data reinforce well-established efficacy and safety profile of Dupixent across age groups
Paris and Tarrytown, N.Y. September 5, 2022. Results from a Phase 3 open-label extension trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) as a maintenance therapy when added to other asthma medications was consistent for up to two years in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma with evidence of type 2…